421 related articles for article (PubMed ID: 22461124)
21. A new era of improving progression-free survival with dual blockade in postmenopausal HR(+), HER2(-) advanced breast cancer.
Jerusalem G; Bachelot T; Barrios C; Neven P; Di Leo A; Janni W; de Boer R
Cancer Treat Rev; 2015 Feb; 41(2):94-104. PubMed ID: 25575443
[TBL] [Abstract][Full Text] [Related]
22. Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer.
Mohd Sharial MSN; Crown J; Hennessy BT
Ann Oncol; 2012 Dec; 23(12):3007-3016. PubMed ID: 22865781
[TBL] [Abstract][Full Text] [Related]
23. New targets for therapy in breast cancer: mammalian target of rapamycin (mTOR) antagonists.
Carraway H; Hidalgo M
Breast Cancer Res; 2004; 6(5):219-24. PubMed ID: 15318929
[TBL] [Abstract][Full Text] [Related]
24. A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure.
Massarweh S; Romond E; Black EP; Van Meter E; Shelton B; Kadamyan-Melkumian V; Stevens M; Elledge R
Breast Cancer Res Treat; 2014 Jan; 143(2):325-32. PubMed ID: 24327334
[TBL] [Abstract][Full Text] [Related]
25. Potential of overcoming resistance to HER2-targeted therapies through the PI3K/Akt/mTOR pathway.
Wilks ST
Breast; 2015 Oct; 24(5):548-55. PubMed ID: 26187798
[TBL] [Abstract][Full Text] [Related]
26. Gene expression profiling of response to mTOR inhibitor everolimus in pre-operatively treated post-menopausal women with oestrogen receptor-positive breast cancer.
Sabine VS; Sims AH; Macaskill EJ; Renshaw L; Thomas JS; Dixon JM; Bartlett JM
Breast Cancer Res Treat; 2010 Jul; 122(2):419-28. PubMed ID: 20480226
[TBL] [Abstract][Full Text] [Related]
27. Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163.
Ellard SL; Clemons M; Gelmon KA; Norris B; Kennecke H; Chia S; Pritchard K; Eisen A; Vandenberg T; Taylor M; Sauerbrei E; Mishaeli M; Huntsman D; Walsh W; Olivo M; McIntosh L; Seymour L
J Clin Oncol; 2009 Sep; 27(27):4536-41. PubMed ID: 19687332
[TBL] [Abstract][Full Text] [Related]
28. Bone effects of mammalian target of rapamycin (mTOR) inhibition with everolimus.
Hadji P; Coleman R; Gnant M
Crit Rev Oncol Hematol; 2013 Aug; 87(2):101-11. PubMed ID: 23838481
[TBL] [Abstract][Full Text] [Related]
29. Mammalian target of rapamycin as a rational therapeutic target for breast cancer treatment.
LoRusso PM
Oncology; 2013; 84(1):43-56. PubMed ID: 23128843
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of everolimus, a novel mTOR inhibitor, against basal-like triple-negative breast cancer cells.
Yunokawa M; Koizumi F; Kitamura Y; Katanasaka Y; Okamoto N; Kodaira M; Yonemori K; Shimizu C; Ando M; Masutomi K; Yoshida T; Fujiwara Y; Tamura K
Cancer Sci; 2012 Sep; 103(9):1665-71. PubMed ID: 22703543
[TBL] [Abstract][Full Text] [Related]
31. [Exemestane-everolimus in HER2-negative, hormonal receptor-positive, post-menopausal metastatic breast cancer with resistance to non-steroidal aromatase inhibitor: a new option].
Gilabert M; Launay S; Gonçalves A
Bull Cancer; 2014 Mar; 101(3):325-33. PubMed ID: 24691195
[TBL] [Abstract][Full Text] [Related]
32. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
Medina PJ; Goodin S
Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
[TBL] [Abstract][Full Text] [Related]
33. Everolimus in hormone receptor-positive advanced breast cancer: targeting receptor-based mechanisms of resistance.
Shtivelband MI
Breast; 2013 Aug; 22(4):405-10. PubMed ID: 23499266
[TBL] [Abstract][Full Text] [Related]
34. The mTOR inhibitor RAD001 sensitizes tumor cells to the cytotoxic effect of carboplatin in breast cancer in vitro.
Liu H; Zang C; Schefe JH; Schwarzlose-Schwarck S; Regierer AC; Elstner E; Schulz CO; Scholz C; Possinger K; Eucker J
Anticancer Res; 2011 Sep; 31(9):2713-22. PubMed ID: 21868512
[TBL] [Abstract][Full Text] [Related]
35. [BOLERO -- another remarkable step in treatment of breast cancer].
Rubovszky G; Láng I
Magy Onkol; 2014 Jun; 58(2):128-32. PubMed ID: 25010761
[TBL] [Abstract][Full Text] [Related]
36. Overcoming endocrine resistance in breast cancer: importance of mTOR inhibition.
Gnant M
Expert Rev Anticancer Ther; 2012 Dec; 12(12):1579-89. PubMed ID: 23253223
[TBL] [Abstract][Full Text] [Related]
37. The mammalian target of rapamycin inhibitor everolimus (RAD001) in early breast cancer: results of a pre-operative study.
Macaskill EJ; Bartlett JM; Sabine VS; Faratian D; Renshaw L; White S; Campbell FM; Young O; Williams L; Thomas JS; Barber MD; Dixon JM
Breast Cancer Res Treat; 2011 Aug; 128(3):725-34. PubMed ID: 20941539
[TBL] [Abstract][Full Text] [Related]
38. Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer.
Boulay A; Rudloff J; Ye J; Zumstein-Mecker S; O'Reilly T; Evans DB; Chen S; Lane HA
Clin Cancer Res; 2005 Jul; 11(14):5319-28. PubMed ID: 16033851
[TBL] [Abstract][Full Text] [Related]
39. Enhancing the efficacy of hormonal agents with selected targeted agents.
Johnston SR
Clin Breast Cancer; 2009 Jun; 9 Suppl 1():S28-36. PubMed ID: 19561004
[TBL] [Abstract][Full Text] [Related]
40. [The drug of the month: everolimus (Afinitor) for the treatment of metastatic breast cancer].
Jerusalem G; Rorive A; Collignon J
Rev Med Liege; 2014 Sep; 69(9):510-7. PubMed ID: 25796760
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
